These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1732548)

  • 1. Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
    Robertson DW; Lacefield WB; Bloomquist W; Pfeifer W; Simon RL; Cohen ML
    J Med Chem; 1992 Jan; 35(2):310-9. PubMed ID: 1732548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LY277359 maleate: a potent and selective 5-HT3 receptor antagonist without gastroprokinetic activity.
    Cohen ML; Bloomquist W; Gidda JS; Lacefield W
    J Pharmacol Exp Ther; 1990 Jul; 254(1):350-5. PubMed ID: 2366187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonism of serotonin3 (5-HT3) receptors within the blood-brain barrier prevents cisplatin-induced emesis in dogs.
    Gidda JS; Evans DC; Cohen ML; Wong DT; Robertson DW; Parli CJ
    J Pharmacol Exp Ther; 1995 May; 273(2):695-701. PubMed ID: 7752072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxa mide, a useful radioligand for 5HT3 receptors.
    Robertson DW; Bloomquist W; Cohen ML; Reid LR; Schenck K; Wong DT
    J Med Chem; 1990 Dec; 33(12):3176-81. PubMed ID: 2258903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General pharmacology of a new potent 5-hydroxytryptamine antagonist.
    Williams PD; Calligaro DO; Colbert WE; Helton DR; Shetler T; Turk JA; Jordan WH
    Arzneimittelforschung; 1991 Mar; 41(3):189-95. PubMed ID: 1867653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides.
    Youssefyeh RD; Campbell HF; Airey JE; Klein S; Schnapper M; Powers M; Woodward R; Rodriguez W; Golec S; Studt W
    J Med Chem; 1992 Mar; 35(5):903-11. PubMed ID: 1548679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the 5-HT3 receptor antagonist properties of ICS 205-930, GR38032F and zacopride.
    Cohen ML; Bloomquist W; Gidda JS; Lacefield W
    J Pharmacol Exp Ther; 1989 Jan; 248(1):197-201. PubMed ID: 2521513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-HT3 receptor antagonists. 2. 4-Hydroxy-3-quinolinecarboxylic acid derivatives.
    Hayashi H; Miwa Y; Ichikawa S; Yoda N; Miki I; Ishii A; Kono M; Yasuzawa T; Suzuki F
    J Med Chem; 1993 Mar; 36(5):617-26. PubMed ID: 8496941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of zatosetron on ipecac-induced emesis in dogs and healthy men.
    Schwartz SM; Goldberg MJ; Gidda JS; Cerimele BJ
    J Clin Pharmacol; 1994 Mar; 34(3):250-4. PubMed ID: 7517409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benzoxazines. II. Synthesis, conformational analysis, and structure--activity relationships of 3,4-dihydro-2H-1,4-benzoxazine-8-carboxamide derivatives as potent and long-acting serotonin-3 (5-HT3) receptor antagonists.
    Kuroita T; Marubayashi N; Sano M; Kanzaki K; Inaba K; Kawakita T
    Chem Pharm Bull (Tokyo); 1996 Nov; 44(11):2051-60. PubMed ID: 8945770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRL 46470A: a highly potent, selective and long acting 5-HT3 receptor antagonist with anxiolytic-like properties.
    Blackburn TP; Baxter GS; Kennett GA; King FD; Piper DC; Sanger GJ; Thomas DR; Upton N; Wood MD
    Psychopharmacology (Berl); 1993; 110(3):257-64. PubMed ID: 7831418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of 6-chloro-3,4-dihydro-4-methyl-2H-1,4-benzoxazine-8-carboxamide derivatives as potent serotonin-3 (5-HT3) receptor antagonists.
    Kuroita T; Sakamori M; Kawakita T
    Chem Pharm Bull (Tokyo); 1996 Apr; 44(4):756-64. PubMed ID: 8681408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New 5-HT3 (serotonin-3) receptor antagonists. IV. Synthesis and structure-activity relationships of azabicycloalkaneacetamide derivatives.
    Kato M; Ito K; Nishino S; Yamakuni H; Takasugi H
    Chem Pharm Bull (Tokyo); 1995 Aug; 43(8):1351-7. PubMed ID: 7553980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-hydroxytryptamine4 receptor agonists facilitate cholinergic transmission in the circular muscle of guinea pig ileum: antagonism by tropisetron and DAU 6285.
    Tonini M; Candura SM; Onori L; Coccini T; Manzo L; Rizzi CA
    Life Sci; 1992; 50(21):PL173-8. PubMed ID: 1315899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GR113808: a novel, selective antagonist with high affinity at the 5-HT4 receptor.
    Gale JD; Grossman CJ; Whitehead JW; Oxford AW; Bunce KT; Humphrey PP
    Br J Pharmacol; 1994 Jan; 111(1):332-8. PubMed ID: 8012715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulant effects of 5-hydroxytryptamine on guinea pig stomach preparations in vitro.
    Buchheit KH; Buhl T
    Eur J Pharmacol; 1994 Sep; 262(1-2):91-7. PubMed ID: 7813582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and pharmacology of 3,4-dihydro-3-oxo-1,4-benzoxazine-8-carboxamide derivatives, a new class of potent serotonin-3 (5-HT3) receptor antagonists.
    Kawakita T; Kuroita T; Yasumoto M; Sano M; Inaba K; Fukuda T; Tahara T
    Chem Pharm Bull (Tokyo); 1992 Mar; 40(3):624-30. PubMed ID: 1611677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of a new class of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid derivatives as highly potent 5-HT3 receptor antagonists.
    Turconi M; Nicola M; Quintero MG; Maiocchi L; Micheletti R; Giraldo E; Donetti A
    J Med Chem; 1990 Aug; 33(8):2101-8. PubMed ID: 1695682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RS 42358-197, a novel and potent 5-HT3 receptor antagonist, in vitro and in vivo.
    Eglen RM; Lee CH; Smith WL; Johnson LG; Whiting RL; Hegde SS
    J Pharmacol Exp Ther; 1993 Aug; 266(2):535-43. PubMed ID: 8355189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis.
    Fernández AG; Puig J; Beleta J; Doménech T; Bou J; Berga P; Gristwood RW; Roberts DJ
    Eur J Pharmacol; 1992 Nov; 222(2-3):257-64. PubMed ID: 1451737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.